S-2529-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jon Husted (R-OH)
What it does
This bill would increase the clarity and predictability of the FDA's process for reviewing applications to switch a drug from prescription-only (Rx) status to over-the-counter (nonprescription) availability. It would establish clearer procedural rules and more predictable timelines for drug manufacturers seeking to make their products available without a prescription. The specific regulatory mechanisms are not detailed in the bill text as introduced.
Who benefits
Pharmaceutical and consumer healthcare companies that manufacture drugs and seek to expand their products to OTC markets. Consumers who would gain easier access to medications currently requiring a doctor's visit and prescription. Patients in rural or underserved areas with limited access to healthcare providers. Uninsured or underinsured individuals who could avoid the cost of a medical visit to obtain certain medications. Generic drug manufacturers who may benefit from a more predictable switch pathway.
Who is hurt
Physicians, nurse practitioners, and other prescribers who may see reduced patient visits if more drugs become available OTC. Pharmacists who currently provide prescription counseling and may face increased demand for informal OTC guidance without compensation. Patients who might use a switched drug without appropriate medical supervision, potentially missing an underlying diagnosis. Health insurers, who may face pressure to cover OTC drugs that were previously covered as prescriptions. Competing OTC drug manufacturers whose market position could be affected by new entrants.
Supporters argue
Supporters argue that the current Rx-to-OTC switch process is opaque and unpredictable, discouraging manufacturers from pursuing switches even when drugs have strong safety profiles for unsupervised use. They contend that expanding OTC access reduces barriers for patients — particularly those without insurance or easy access to a doctor — and that countries like the United Kingdom already make many of these drugs available without a prescription with no significant safety incidents. Greater clarity in the FDA process, they argue, would accelerate consumer access to safe, effective medications.
Opponents argue
Opponents argue that loosening the prescription requirement for more drugs — even through a procedural streamlining bill — increases the risk that patients will self-diagnose and self-treat conditions that require professional evaluation, potentially delaying care for serious illnesses. They contend that the existing FDA review process, while slow, provides important safety guardrails, and that making it more "predictable" for manufacturers could tilt the process toward industry interests at the expense of rigorous public health review. Critics may also note that the bill's lack of specific detail makes it difficult to assess what safeguards would remain in place.
Constitutional context
Congress has broad authority to regulate drug safety and labeling under the Commerce Clause (Art. I, §8, cl. 3), and the FDA's authority to classify drugs as prescription or OTC derives from statutes enacted under that power. Post-Loper Bright (2024), any FDA regulations implementing this bill's procedural requirements would face independent judicial review rather than automatic deference, meaning courts would assess whether the agency's rules stay within the bounds of the authorizing statute.
Checks and balances
The FDA (executive branch) would gain clearer procedural authority to manage switch applications; Congress retains oversight through the HELP Committee, and post-Loper Bright, federal courts would independently review any resulting agency rules for statutory fidelity.
Historical precedent
The Over-the-Counter Monograph Safety, Innovation, and Reform Act (2020) similarly modernized the FDA's OTC drug review process, establishing clearer timelines and administrative procedures for OTC monograph drugs.